BioCentriq, a global cell-based therapy Contract Development and Manufacturing Organization (CDMO), has announced the successful completion of its latest round of fundraising, securing $29.2M in capital investment. The funds will be strategically deployed to enhance BioCentriq's facilities, invest in advanced technologies, and expand its talented team of experts to meet the increasing demand for scalable cell therapy solutions.